These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 30389815)

  • 41. Quality control in PET/CT and PET/MRI: Results of a survey amongst European countries.
    Reynés-Llompart G; Zorz A; Boellaard R; Ptáček J; Pike L; Soret M; Vandenberghe S; Matheoud R
    Phys Med; 2022 Jul; 99():16-21. PubMed ID: 35598481
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluating the Role of F-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Scanning in the Staging of Patients With Stage IIIB Cervical Carcinoma and the Impact on Treatment Decisions.
    Morkel M; Ellmann A; Warwick J; Simonds H
    Int J Gynecol Cancer; 2018 Feb; 28(2):379-384. PubMed ID: 29324535
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Understanding positon emission tomography (PET) with [18F]-FDG in clinical oncology. Informations dedicated to patients and relatives].
    Bourguet P; Brusco S; Corone C; Devillers A; Foehrenbach H; Lumbroso JD; Maszelin P; Montravers F; Moretti JL; Rain JD; Talbot JN; Carretier J; Leichtnam-Dugarin L; Delavigne V; Philip T; Fervers B; ; ; ; ; ; ;
    Bull Cancer; 2005 Jul; 92(7):723-32. PubMed ID: 16123010
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Whole-body
    Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
    Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dual-time point
    Parghane RV; Basu S
    Semin Nucl Med; 2017 Jul; 47(4):373-391. PubMed ID: 28583277
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 18F-FDG PET/CT: Therapy Response Assessment Interpretation (Hopkins Criteria) and Survival Outcomes in Lung Cancer Patients.
    Sheikhbahaei S; Mena E; Marcus C; Wray R; Taghipour M; Subramaniam RM
    J Nucl Med; 2016 Jun; 57(6):855-60. PubMed ID: 26837337
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of
    Dolci C; Ceppi L; Guerra L; Crivellaro C; Lamanna M; Adorni M; Elisei F; Bonazzi CM; Sina F; Fruscio R; Messa C
    Int J Gynecol Cancer; 2019 Oct; 29(8):1298-1303. PubMed ID: 31366569
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Operational radiation safety for PET-CT, SPECT-CT, and cyclotron facilities.
    Zanzonico P; Dauer L; St Germain J
    Health Phys; 2008 Nov; 95(5):554-70. PubMed ID: 18849690
    [TBL] [Abstract][Full Text] [Related]  

  • 49. What
    Turgeon GA; Iravani A; Akhurst T; Beaulieu A; Callahan JW; Bressel M; Cole AJ; Everitt SJ; Siva S; Hicks RJ; Ball DL; Mac Manus MP
    J Nucl Med; 2019 Mar; 60(3):328-334. PubMed ID: 30030343
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [18F]Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET)/Computed Tomography (CT) in Suspected Recurrent Breast Cancer: A Prospective Comparative Study of Dual-Time-Point FDG-PET/CT, Contrast-Enhanced CT, and Bone Scintigraphy.
    Hildebrandt MG; Gerke O; Baun C; Falch K; Hansen JA; Farahani ZA; Petersen H; Larsen LB; Duvnjak S; Buskevica I; Bektas S; Søe K; Jylling AM; Ewertz M; Alavi A; Høilund-Carlsen PF
    J Clin Oncol; 2016 Jun; 34(16):1889-97. PubMed ID: 27001573
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): a European survey conducted by the European Society for Medical Oncology (ESMO) young oncologists committee.
    Califano R; Karamouzis MV; Banerjee S; de Azambuja E; Guarneri V; Hutka M; Jordan K; Kamposioras K; Martinelli E; Corral J; Postel-Vinay S; Preusser M; Porcu L; Torri V
    Lung Cancer; 2014 Jul; 85(1):74-80. PubMed ID: 24746176
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Staging of locally advanced breast cancer and the prediction of response to neoadjuvant chemotherapy: complementary role of scintimammography and 18F-FDG PET/CT.
    Evangelista L; Cervino AR; Michieletto S; Saibene T; Orvieto E; Bozza F; Ghiotto C
    Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):205-215. PubMed ID: 25501326
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Access, knowledge and experience with fluorodeoxyglucose positron emission tomography/computed tomography in infection management: a survey of Australia and New Zealand infectious diseases physicians and microbiologists.
    Douglas AP; Thursky KA; Worth LJ; Harrison SJ; Hicks RJ; Slavin MA
    Intern Med J; 2019 May; 49(5):615-621. PubMed ID: 30230669
    [TBL] [Abstract][Full Text] [Related]  

  • 54. FDG PET/CT interobserver agreement in head and neck cancer: FDG and CT measurements of the primary tumor site.
    Jackson T; Chung MK; Mercier G; Ozonoff A; Subramaniam RM
    Nucl Med Commun; 2012 Mar; 33(3):305-12. PubMed ID: 22227560
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pulmonary Scintigraphy for the Diagnosis of Acute Pulmonary Embolism: A Survey of Current Practices in Australia, Canada, and France.
    Le Roux PY; Pelletier-Galarneau M; De Laroche R; Hofman MS; Zuckier LS; Roach P; Vuillez JP; Hicks RJ; Le Gal G; Salaun PY
    J Nucl Med; 2015 Aug; 56(8):1212-7. PubMed ID: 26135110
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Diagnostic Reference Levels of CT Radiation Dose in Whole-Body PET/CT.
    Jallow N; Christian P; Sunderland J; Graham M; Hoffman JM; Nye JA
    J Nucl Med; 2016 Feb; 57(2):238-41. PubMed ID: 26564326
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Improving the Diagnostic Performance of
    Swart LE; Gomes A; Scholtens AM; Sinha B; Tanis W; Lam MGEH; van der Vlugt MJ; Streukens SAF; Aarntzen EHJG; Bucerius J; van Assen S; Bleeker-Rovers CP; van Geel PP; Krestin GP; van Melle JP; Roos-Hesselink JW; Slart RHJA; Glaudemans AWJM; Budde RPJ
    Circulation; 2018 Oct; 138(14):1412-1427. PubMed ID: 30018167
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe).
    Nanni C; Zamagni E; Versari A; Chauvie S; Bianchi A; Rensi M; Bellò M; Rambaldi I; Gallamini A; Patriarca F; Gay F; Gamberi B; Cavo M; Fanti S
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):414-21. PubMed ID: 26475305
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Perceived misinterpretation rates in oncologic 18F-FDG PET/CT studies: a survey of referring physicians.
    Karantanis D; Kalkanis D; Czernin J; Herrmann K; Pomykala KL; Bogsrud TV; Subramaniam RM; Lowe VJ; Allen-Auerbach MS
    J Nucl Med; 2014 Dec; 55(12):1925-9. PubMed ID: 25453041
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Multimodality imaging in Europe: a survey by the European Association of Nuclear Medicine (EANM) and the European Society of Radiology (ESR).
    Cuocolo A; Breatnach E
    Eur J Nucl Med Mol Imaging; 2010 Jan; 37(1):163-7. PubMed ID: 19915843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.